These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16402138)

  • 1. Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects.
    Vessières A; Top S; Beck W; Hillard E; Jaouen G
    Dalton Trans; 2006 Jan; (4):529-41. PubMed ID: 16402138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen-receptor modulators (SERMs) in the cyclopentadienylrhenium tricarbonyl series: synthesis and biological behaviour.
    Top S; Vessières A; Pigeon P; Rager MN; Huché M; Salomon E; Cabestaing C; Vaissermann J; Jaouen G
    Chembiochem; 2004 Aug; 5(8):1104-13. PubMed ID: 15300835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
    Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
    J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
    Saji S; Kuroi K
    Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivity and antiproliferative activity of ferrocenyl-tamoxifen adducts with cyclodextrins against hormone-independent breast-cancer cell lines.
    Buriez O; Heldt JM; Labbé E; Vessières A; Jaouen G; Amatore C
    Chemistry; 2008; 14(27):8195-203. PubMed ID: 18668496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
    Gewirtz DA; Di X; Walker TD; Sawyer ST
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
    Shang Y
    Nat Rev Cancer; 2006 May; 6(5):360-8. PubMed ID: 16633364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro.
    Vessières A; Top S; Pigeon P; Hillard E; Boubeker L; Spera D; Jaouen G
    J Med Chem; 2005 Jun; 48(12):3937-40. PubMed ID: 15943467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
    Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG
    Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR; Bartlett JM; Canney P; Verrill M
    Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology.
    Nilsson S; Koehler KF
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):15-25. PubMed ID: 15667591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
    Powles TJ
    Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of transcriptional activity of the oestrogen receptor with sodium iodide symporter as an imaging reporter gene.
    Kang JH; Chung JK; Lee YJ; Kim KI; Jeong JM; Lee DS; Lee MC
    Nucl Med Commun; 2006 Oct; 27(10):773-7. PubMed ID: 16969258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An expeditious synthesis of tamoxifen, a representative SERM (selective estrogen receptor modulator), via the three-component coupling reaction among aromatic aldehyde, cinnamyltrimethylsilane, and beta-chlorophenetole.
    Shiina I; Sano Y; Nakata K; Suzuki M; Yokoyama T; Sasaki A; Orikasa T; Miyamoto T; Ikekita M; Nagahara Y; Hasome Y
    Bioorg Med Chem; 2007 Dec; 15(24):7599-617. PubMed ID: 17904372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
    Frasor J; Chang EC; Komm B; Lin CY; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
    Cancer Res; 2006 Jul; 66(14):7334-40. PubMed ID: 16849584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.